Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

被引:94
作者
Bleecker, ER
Welch, MJ
Weinstein, SF
Kalberg, C
Johnson, M
Edwards, L
Rickard, KA
机构
[1] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[2] Allergy & Asthma Med Grp, San Diego, CA USA
[3] Allergy & Asthma Specialists Med Grp, Huntington Beach, CA USA
[4] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
关键词
fluticasone propionate; asthma; inhaled corticosteroids; leukotriene modifiers; zafirlukast;
D O I
10.1067/mai.2000.106043
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Few studies have compared the efficacy of inhaled corticosteroids and leukotriene modifiers for the treatment of persistent asthma. Objective: Our purpose was to compare the efficacy of a low dose of inhaled fluticasone propionate (FP) with that of oral zafirlukast in the treatment of persistent asthma previously treated with short-acting beta(2)-agonists alone. Methods: A 12-week, randomized, double-blind, double-dummy, multicenter study was conducted in 451 patients aged 12 years and older with asthma who were symptomatic on short-acting beta(2)-agonists alone. After an 8- to 14-day run-in period; patients were randomized to treatment with FP 88 pg twice daily or zafirlukast 20 mg twice daily. Results: Treatment with FP was more effective than treatment with zafirlukast in increasing morning FEV1 (by 0.42 L vs 0.20 L over baseline, P < .001), morning peak expiratory flow (by 49.94 L/min vs 11.68 L/min over baseline, P < .001), and evening PEF (by 38.91 L/min vs 10.50 L/min over baseline, P < .001). Statistically significant differences between the two treatments in FEV1 were noted after the first observation (week 4) and in morning and evening peak expiratory flow by week 2, Mean change in percentage of symptom-free days was greater with FP than with zafirlukast (28.5% of days vs 15.6% of days, P < .001) and FP significantly increased the percentage of rescue-free days by 40.4% of days compared with 24.2% of days with zafirlukast (P < .001). Treatment with FP significantly reduced albuterol use by 2.39 puffs per day compared with 1.45 puffs per day (P < .001) and increased the percentage of nights with no awakenings by 21.2% of nights compared with 8.0% of nights with zafirlukast (P < .001). Conclusion: The clinical effectiveness of a low dose of FP as first-line therapy in patients with persistent asthma who are symptomatic on Pz-agonists alone is superior to that of zafirlukast.
引用
收藏
页码:1123 / 1129
页数:7
相关论文
共 20 条
[1]  
[Anonymous], 1987, AM REV RESPIR DIS, V136, P225
[2]   Efficacy and safety of inhaled corticosteroids - New developments [J].
Barnes, PJ ;
Pedersen, S ;
Busse, WW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (03) :S1-S53
[3]   Inhaled corticosteroids and the prevention of readmission to hospital for asthma [J].
Blais, L ;
Ernst, P ;
Boivin, JF ;
Suissa, S .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (01) :126-132
[4]  
Busse W, 1999, AM J RESP CRIT CARE, V159, pA628
[5]  
CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659
[6]   Inhaled steroids and the risk of hospitalization for asthma [J].
Donahue, JG ;
Weiss, ST ;
Livingston, JM ;
Goetsch, MA ;
Greineder, DK ;
Platt, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (11) :887-891
[7]   Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment [J].
Drazen, JM ;
Yandava, CN ;
Dubé, L ;
Szczerback, N ;
Hippensteel, R ;
Pillari, A ;
Israel, E ;
Schork, N ;
Silverman, ES ;
Katz, DA ;
Drajesk, J .
NATURE GENETICS, 1999, 22 (02) :168-170
[8]   Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Yes [J].
Drazen, JM ;
Israel, E .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (06) :1697-1698
[9]   Treatment of asthma with drugs modifying the leukotriene pathway [J].
Drazen, JM ;
Israel, E ;
O'Byrne, PM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (03) :197-206
[10]   Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study [J].
Fish, JE ;
Kemp, JP ;
Lockey, RF ;
Glass, M ;
Hanby, LA ;
Bonuccelli, CM ;
Bronsky, E ;
Condemi, J ;
Goldstein, S ;
Norton, J ;
Rosenthal, R ;
Silvers, W ;
Tinkelman, D ;
Weisberg, S ;
Winder, J .
CLINICAL THERAPEUTICS, 1997, 19 (04) :675-690